TY  - JOUR
AU  - Mirjanić-Azarić, Bosa
AU  - Stanković, Siniša
AU  - Radić Savić, Žana
AU  - Malčić-Žanić, Dragana
AU  - Ninić, Ana
AU  - Vuković, Marija
AU  - Nežić, Lana
AU  - Skrbić, Ranko
AU  - Bogavac-Stanojević, Nataša
PY  - 2024
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5758
AB  - Background: Recent findings point to the key role of
cathepsin S (CTSS) in the survival of malignant cells, as
well as the significance of the anti-apoptotic properties of
high-density lipoprotein (HDL) that contribute to enhanced
cell survival. The purpose of this study is to analyse CTSS
as a potential biomarker in lymphoma. Also, in order to
better understand the role of CTSS in the origin and devel-
opment of lymphoma, its association with cystatin C (Cys
C), lipids, and inflammatory markers was analysed.
Methods: The study included 90 subjects: 11 Hodgkin (HL)
and 44 B-cell non-Hodgkin lymphoma (NHL) patients, as
well as 35 healthy subjects. CTSS was determined using
the Invitrogen ELISA kit (Thermo Fisher Scientific, Inc.,
Waltham, MA, USA). The non-denaturing 3%–31% poly-
acrylamide gradient gel electrophoresis method was used
to separate plasma HDL particles.
AB  - Uvod: Novija otkri}a ukazuju na klju~nu ulogu katepsina S
(CTSS) u pre`ivljavanju malignih }elija, kao i na zna~aj anti-
apoptoti~kih osobina lipoproteina visoke gusto}e (HDL)
koje doprinose ve}em pre`ivljavanja }elija. Cilj ove studije
je analizirati CTSS kao potencijalni biomarker kod limfomu.
Tako|e, kako bi se bolje razumela uloga CTSS-a u nastan-
ku i razvoju limfoma, analizirana je njegova povezanost sa
cistatinom C (Cys C), lipidima i upalnim markerima.
Metode: U istra`ivanje je bilo uklju~eno 90 ispitanika: 11
bolesnika sa Hodgkinovim (HL) i 44 bolesnika sa B-}elij-
skim ne-Hodgkinovim limfomom (NHL), te 35 zdravih ispi-
tanika. Za merenje serumskog CTSS je kori{}en Invitrogen
ELISA kit (Thermo Fisher Scientific, Inc., Waltham, MA,
SAD). HDL subfrakcije su razdvojene metodom vertikalne
elektroforeze na gradijentu poliakrilamida.
PB  - Društvo medicinskih biohemičara Srbije, Beograd
T2  - Journal of Medical Biochemistry
T1  - Assessment of the diagnostic value of serum cathepsin s and its correlation with hdl  ubclasses in patients with non-hodgkin’s lymphoma
T1  - Procena dijagnostičke vrednosti serumskog katepsina S i njegove korelacije sa HDL podklasama kod pacijenata sa ne-Hodgkinovim limfomom
VL  - 43
IS  - 5
SP  - 711
EP  - 719
DO  - 10.5937/jomb0-48959
ER  - 

@article{
author = "Mirjanić-Azarić, Bosa and Stanković, Siniša and Radić Savić, Žana and Malčić-Žanić, Dragana and Ninić, Ana and Vuković, Marija and Nežić, Lana and Skrbić, Ranko and Bogavac-Stanojević, Nataša",
year = "2024",
abstract = "Background: Recent findings point to the key role of
cathepsin S (CTSS) in the survival of malignant cells, as
well as the significance of the anti-apoptotic properties of
high-density lipoprotein (HDL) that contribute to enhanced
cell survival. The purpose of this study is to analyse CTSS
as a potential biomarker in lymphoma. Also, in order to
better understand the role of CTSS in the origin and devel-
opment of lymphoma, its association with cystatin C (Cys
C), lipids, and inflammatory markers was analysed.
Methods: The study included 90 subjects: 11 Hodgkin (HL)
and 44 B-cell non-Hodgkin lymphoma (NHL) patients, as
well as 35 healthy subjects. CTSS was determined using
the Invitrogen ELISA kit (Thermo Fisher Scientific, Inc.,
Waltham, MA, USA). The non-denaturing 3%–31% poly-
acrylamide gradient gel electrophoresis method was used
to separate plasma HDL particles., Uvod: Novija otkri}a ukazuju na klju~nu ulogu katepsina S
(CTSS) u pre`ivljavanju malignih }elija, kao i na zna~aj anti-
apoptoti~kih osobina lipoproteina visoke gusto}e (HDL)
koje doprinose ve}em pre`ivljavanja }elija. Cilj ove studije
je analizirati CTSS kao potencijalni biomarker kod limfomu.
Tako|e, kako bi se bolje razumela uloga CTSS-a u nastan-
ku i razvoju limfoma, analizirana je njegova povezanost sa
cistatinom C (Cys C), lipidima i upalnim markerima.
Metode: U istra`ivanje je bilo uklju~eno 90 ispitanika: 11
bolesnika sa Hodgkinovim (HL) i 44 bolesnika sa B-}elij-
skim ne-Hodgkinovim limfomom (NHL), te 35 zdravih ispi-
tanika. Za merenje serumskog CTSS je kori{}en Invitrogen
ELISA kit (Thermo Fisher Scientific, Inc., Waltham, MA,
SAD). HDL subfrakcije su razdvojene metodom vertikalne
elektroforeze na gradijentu poliakrilamida.",
publisher = "Društvo medicinskih biohemičara Srbije, Beograd",
journal = "Journal of Medical Biochemistry",
title = "Assessment of the diagnostic value of serum cathepsin s and its correlation with hdl  ubclasses in patients with non-hodgkin’s lymphoma, Procena dijagnostičke vrednosti serumskog katepsina S i njegove korelacije sa HDL podklasama kod pacijenata sa ne-Hodgkinovim limfomom",
volume = "43",
number = "5",
pages = "711-719",
doi = "10.5937/jomb0-48959"
}

Mirjanić-Azarić, B., Stanković, S., Radić Savić, Ž., Malčić-Žanić, D., Ninić, A., Vuković, M., Nežić, L., Skrbić, R.,& Bogavac-Stanojević, N.. (2024). Assessment of the diagnostic value of serum cathepsin s and its correlation with hdl  ubclasses in patients with non-hodgkin’s lymphoma. in Journal of Medical Biochemistry
Društvo medicinskih biohemičara Srbije, Beograd., 43(5), 711-719.
https://doi.org/10.5937/jomb0-48959

Mirjanić-Azarić B, Stanković S, Radić Savić Ž, Malčić-Žanić D, Ninić A, Vuković M, Nežić L, Skrbić R, Bogavac-Stanojević N. Assessment of the diagnostic value of serum cathepsin s and its correlation with hdl  ubclasses in patients with non-hodgkin’s lymphoma. in Journal of Medical Biochemistry. 2024;43(5):711-719.
doi:10.5937/jomb0-48959 .

Mirjanić-Azarić, Bosa, Stanković, Siniša, Radić Savić, Žana, Malčić-Žanić, Dragana, Ninić, Ana, Vuković, Marija, Nežić, Lana, Skrbić, Ranko, Bogavac-Stanojević, Nataša, "Assessment of the diagnostic value of serum cathepsin s and its correlation with hdl  ubclasses in patients with non-hodgkin’s lymphoma" in Journal of Medical Biochemistry, 43, no. 5 (2024):711-719,
https://doi.org/10.5937/jomb0-48959 . .

TY  - JOUR
AU  - Mirjanić-Azarić, Bosa
AU  - Stanković, Siniša
AU  - Nezić, Lana
AU  - Radić-Savić, Žana
AU  - Malčić- Zanić, Dragana
AU  - Skrbić, Ranko
AU  - Kotur-Stevuljević, Jelena
AU  - Bogavac-Stanojević, Nataša
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5286
AB  - Newer research points to alterations in the plasma redox status and the HDL subclass distributions in cancer. We aimed to assess the redox status and the HDL subclass distributions, lipids, and inflammatory markers in lymphoma patients in order to determine whether they were correlated with changes in FDG-PET/CT scans. At the beginning of this study, redox status, HDL subclasses, lipids, and inflammation biomarkers were determined in 58 patients with lymphoma (Hodgkin lymphoma, n=11 and non-Hodgkin lymphoma, n=47), and these same measurements were reassessed during their ensuing treatment (in 25 patients). Initially, the total oxidation status (TOS), the prooxidant–antioxidant balance (PAB), the OS index (OSI), the total protein sulfhydryl groups (SH-groups), and the advanced oxidation protein products (AOPP) were significantly higher in lymphoma patients as compared to healthy subjects, but the total antioxidant status (TAS) was significantly reduced. The PAB had a strong correlation with the CRP and interleukin-6 (rho=0.726, p[removed]
PB  - Frontiers Media SA
T2  - Frontiers in Oncology
T1  - Analysis of redox status and HDL subclasses in patients with lymphoma and the associations with FDG-PET/CT findings
VL  - 13
DO  - 10.3389/fonc.2023.1221414
ER  - 

@article{
author = "Mirjanić-Azarić, Bosa and Stanković, Siniša and Nezić, Lana and Radić-Savić, Žana and Malčić- Zanić, Dragana and Skrbić, Ranko and Kotur-Stevuljević, Jelena and Bogavac-Stanojević, Nataša",
year = "2023",
abstract = "Newer research points to alterations in the plasma redox status and the HDL subclass distributions in cancer. We aimed to assess the redox status and the HDL subclass distributions, lipids, and inflammatory markers in lymphoma patients in order to determine whether they were correlated with changes in FDG-PET/CT scans. At the beginning of this study, redox status, HDL subclasses, lipids, and inflammation biomarkers were determined in 58 patients with lymphoma (Hodgkin lymphoma, n=11 and non-Hodgkin lymphoma, n=47), and these same measurements were reassessed during their ensuing treatment (in 25 patients). Initially, the total oxidation status (TOS), the prooxidant–antioxidant balance (PAB), the OS index (OSI), the total protein sulfhydryl groups (SH-groups), and the advanced oxidation protein products (AOPP) were significantly higher in lymphoma patients as compared to healthy subjects, but the total antioxidant status (TAS) was significantly reduced. The PAB had a strong correlation with the CRP and interleukin-6 (rho=0.726, p[removed]",
publisher = "Frontiers Media SA",
journal = "Frontiers in Oncology",
title = "Analysis of redox status and HDL subclasses in patients with lymphoma and the associations with FDG-PET/CT findings",
volume = "13",
doi = "10.3389/fonc.2023.1221414"
}

Mirjanić-Azarić, B., Stanković, S., Nezić, L., Radić-Savić, Ž., Malčić- Zanić, D., Skrbić, R., Kotur-Stevuljević, J.,& Bogavac-Stanojević, N.. (2023). Analysis of redox status and HDL subclasses in patients with lymphoma and the associations with FDG-PET/CT findings. in Frontiers in Oncology
Frontiers Media SA., 13.
https://doi.org/10.3389/fonc.2023.1221414

Mirjanić-Azarić B, Stanković S, Nezić L, Radić-Savić Ž, Malčić- Zanić D, Skrbić R, Kotur-Stevuljević J, Bogavac-Stanojević N. Analysis of redox status and HDL subclasses in patients with lymphoma and the associations with FDG-PET/CT findings. in Frontiers in Oncology. 2023;13.
doi:10.3389/fonc.2023.1221414 .

Mirjanić-Azarić, Bosa, Stanković, Siniša, Nezić, Lana, Radić-Savić, Žana, Malčić- Zanić, Dragana, Skrbić, Ranko, Kotur-Stevuljević, Jelena, Bogavac-Stanojević, Nataša, "Analysis of redox status and HDL subclasses in patients with lymphoma and the associations with FDG-PET/CT findings" in Frontiers in Oncology, 13 (2023),
https://doi.org/10.3389/fonc.2023.1221414 . .